对PIK3R1突变和野生型乳腺癌的比较基因组分析
Melody A Cobleigh1, Kayla Viets Layng2, Elizabeth Mauer2
1Rush University Medical Center, 1620 W Harrison St, Chicago, IL, 60612, USA. melody_cobleigh@rush.edu.
Breast cancer research and treatment
|December 28, 2023
概括
在三阴性乳腺癌 (TNBC) 中,PIK3R1突变比其他亚型更频繁. 这项研究强调PIK3R1作为TNBC的潜在治疗点,除了它在HER2-/HR+乳腺癌中的已知作用外.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学是一种遗传学.
- 分子生物学分子生物学
背景情况:
- PIK3R1基因编码PI3K信号通路的一个关键调节子单元.
- 之前的研究表明,PIK3R1的改变在乳腺癌中很常见,但缺乏全面的基因组表征.
研究的目的:
- 为了研究患有PIK3R1突变的乳腺癌患者的基因组景观.
- 确定不同乳腺癌亚型中PIK3R1变化的频率和模式.
主要方法:
- 对6009名乳腺癌患者病历进行了回顾性分析.
- 来自Tempus xT固体瘤试验的下一代测序 (NGS) 数据.
- 基于PIK3R1突变 (短变异,拷贝数变化) 和受体状态 (HER2,HR) 的分类.
主要成果:
- PIK3R1突变发生在6%的三阴性乳腺癌 (TNBC),2%的HER2-/HR+和2.3%的HER2+病例中.
- 丰富PTEN,TP53和NF1的共同突变;减少PIK3CA共同突变;在PIK3R1-突变的HER2-样本中增加瘤突变负担.
- 在PIK3R1-突变HER2-瘤中增加PIK3R1RNA表达.
结论:
- 这项研究代表了对乳腺癌中PIK3R1突变格局的最大分析.
- 与HER2+或HER2-/HR+亚型相比,PIK3R1突变在TNBC中明显更为普遍.
- PIK3R1成为潜在的治疗点,不仅在HER2-/HR+乳腺癌中,而且在TNBC中也是如此.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K